This study aimed to assess a four-marker protein panel (4MP)’s performance, including the precursor form of surfactant protein B, cancer antigen 125, carcinoembryonic antigen, and cytokeratin-19, for predicting lung cancer in a cohort enriched with never- and ever-smokers. Blinded pre-diagnostic plasma samples collected within 2 years prior to a lung cancer diagnosis from 25 cases and 100 sex-, age-, and smoking-matched controls were obtained from the Physicians’ Health Study (PHS). The 4MP yielded AUC performance estimates of 0.76 (95% CI: 0.61–0.92) and 0.69 (95% CI: 0.56–0.82) for predicting lung cancer within one year and within two years of diagnosis, respectively. When stratifying into ever-smokers and never-smokers, the 4MP had respective AUCs of 0.77 (95% CI: 0.63–0.92) and 0.72 (95% CI: 0.17–1.00) for a 1-year risk of lung cancer. The AUCs of the 4MP for predicting metastatic lung cancer within one year and two years of the blood draw were 0.95 (95% CI: 0.87–1.00) and 0.78 (95% CI: 0.62–0.94), respectively. Our findings indicate that a blood-based biomarker panel may be useful in identifying ever- and never-smokers at high risk of a diagnosis of lung cancer within one-to-two years.
本研究旨在评估一个包含表面活性蛋白B前体、癌抗原125、癌胚抗原和细胞角蛋白19的四标志物蛋白组（4MP）在预测从不吸烟者和曾吸烟者队列中肺癌发生风险的表现。研究样本来自“医师健康研究”（PHS），包含25例肺癌患者及100例性别、年龄和吸烟状况匹配的对照者，所有样本均为肺癌诊断前2年内采集的盲法预诊断血浆样本。该4MP模型预测诊断前1年内及2年内肺癌的受试者工作特征曲线下面积（AUC）分别为0.76（95% CI：0.61–0.92）和0.69（95% CI：0.56–0.82）。按吸烟史分层分析显示，4MP预测曾吸烟者和从不吸烟者1年内肺癌风险的AUC分别为0.77（95% CI：0.63–0.92）和0.72（95% CI：0.17–1.00）。在预测采血后1年内及2年内发生转移性肺癌方面，4MP的AUC分别为0.95（95% CI：0.87–1.00）和0.78（95% CI：0.62–0.94）。我们的研究结果表明，基于血液的生物标志物组合可能有助于识别1-2年内具有肺癌高风险的曾吸烟者与从不吸烟者。
肿瘤(癌症)患者之家